The Extroducer® 2.0 receives 510(k) clearance by the US FDA
Extroducer® 2.0 får 510(k)-godkännande från amerikanska FDA
SmartCella utökar patentskyddet för Extroducer® till USA och Japan
SmartCella expands patent for the Extroducer® into the US and Japan
Academic program licensing agreement signed with University Medical Centre Ljubljana
Extroducer® data for intramyocardial delivery presented at EuroPCR 2026 in Paris
SmartCella and Heqet Therapeutics enter into licensing agreement regarding the Extroducer® delivery platform
SmartCella och Heqet Therapeutics ingår licensavtal avseende leveransplattformen Extroducer®
SmartCella initiates Phase I/IIa clinical study with Extroducer® for targeted delivery of chemotherapy in pancreatic cancer
SmartCella inleder klinisk fas I/IIa studie med Extroducer® för riktad leverans av cytostatika vid bukspottkörtelcancer
Let’s pioneer the future of targeted therapies together